“Cannabinoids have intraocular pressure (IOP) lowering effects, thus, they have a therapeutic potential in the treatment of glaucoma.
Our aim was to develop a safer, cannabinoid type anti-glaucoma agent, a topically applied soft analogue, that has local, but no systemic effect.
The lead compound chosen was a nitrogen-containing cannabinoid analogue that was shown to have IOP lowering activity.
A full library of possible soft drugs was generated and the structures were ranked based on the closeness of calculated properties to those of the lead compound.
The lead compound has been synthesized, and a preliminary pharmacological study was performed.
The structure-activity relationship and pharmacological results indicate a good possibility for the development of a safe, soft anti-glaucoma agent.”